




Evaluating new non-invasive screening tests for colorectal cancer: An in-depth international perspective

Robert S. Bresalier, Graeme P. Young, Carlo Senore











WEO The voice of world endoscopy

An efficient strategy for evaluating new noninvasive screening tests for colorectal cancer: The guiding principles

Bresalier* R.S., Senore*, C., Young*, G.P., Allison, J., Benamouzig, R, Benton, S., Bossuyt, P.M., Caro, L., Carvalho, B., Chiu, H.M., Coupe, V.M.H., de Klaver, W., de Klerk, C.M., Dekker, E., Dolwani, S., Fraser, C.G., Grady, W.M., Guittet, L., Gupta, S., Halloran, S.P., Haug, U., Hoff, G., Itzkowitz, S.H., Kortlever, T.L., Koulauzidis, A., Ladabaum, U., Lauby-Secretan, B., Leja, M., Levin, B., Levin, T.R., Macrae, F., Meijer, G.A., Melson, J., O'Morain, C., Parry, S., Rabeneck, L., Ransohoff, D.F., Saenz, R., Saito, H., Sanduleanu, S., Schoen, R.E., Selby, K., Singh, H., Steele, R.J.C., Sung, J.J.Y., Symonds, E., Winawer, S.J. (Members of the WEO CRC Screening New Test Evaluation Expert Working Group)

Gut 2023;72:1904-1918



Topics Addressed in Each of the Principles Established by the Consensus Process

Principle Number	Topic
1	Desired outcomes of CRC screening
2	Screening is a multi-step process
3	A screening test identifies individuals with an increased likelihood of CRC and/or advanced precursor lesions
4	Nature of precursor lesions most important to detect
5	New biomarkers might detect lesions with a different natural history
6	Outcomes to be estimated in a screening population
7	Expectations of a new non-invasive test
8	An adjustable test positivity threshold accommodates different program goals
9	Predicting value by paired comparison to a proven non-invasive test
10	Evaluation proceeds through increasingly complex phases
11	Accuracy required for evaluation in a screening population
12	Analytic specifications, standards, and performance

Gut 2023;72:1904-1918



Background & Aim

- Special issue of Digestive Diseases and Sciences Commissioned to Expand These and Related Topics
- Fully Commissioned
- International Author Representation

Do the guiding principles apply: Lessons from the commercial non-invasive tests?

Josh Melson (USA)

 Validation of a new test for CRC screening: How we did it

Beatriz Carvalho and Veerle Coupe (Netherlands)

 Does colonoscopy as a first (and invasive) screening test still make sense?
 Point/Counterpoint

> Yes Douglas Rex (USA) No Han-Mo Chiu (Taiwan)

 How good is FIT as a comparator in development of new non-invasive screening tests and what is its role?

Carlo Senore (Italy)

Does an adjustable positivity threshold for FIT and other non-invasive tests make sense?
Graeme Young (Australia)

Modelling and the use of surrogate endpoints: Is this a valid approach?

Uri Ladabaum (USA)



- Evaluating non-invasive tests for colorectal cancer-sample size and study design Patrick Bossuyt (Netherlands)
- How good is good enough: What should the target be for colon cancer screening?


US perspective-David Lieberman (USA)
European perspective- Evelien Dekker (Netherlands)

- •Regulatory challenges in bringing new tests to clinical practice Gerard Davis (Abbott Labs)
- •When should colon cancer screening begin? The impact of early-onset colorectal cancer and the reality of an unscreened older population (point/counterpoint)

Screening should begin at age 45 -Iris Lansdorp (Netherlands) Screening at age 45 is not practical Linda Rabeneck (Canada)

- Are non-invasive multi-cancer early cancer detection tests the future?
 William Grady (USA)
- •Risk stratification and the role of Al in non-invasive testing for colorectal cancer Han-Mo Chiu (Taiwan)









World Endoscopy Organization

